Dr. Taylor Doherty

​​​Taylor Alan Doherty

Dr. Taylor A. Doherty is Professor of medicine and Chief of the Division of Allergy and Immunology .​ His studies have led to high impact publications in the fields of asthma, airway remodeling, aspirin exacerbated respiratory disease (AERD), and group 2 innate lymphoid cell (ILC2) biology.

About the Lab

Dr. Doherty’s initial research identified novel therapeutic targets for the airway inflammation and remodeling that occur in chronic asthma pathology.  The Doherty lab has since developed a focus on innate type 2 lung responses that contribute to asthma and allergic airway disease.  We have identified novel mechanisms that regulate group 2 innate lymphoid cells (ILC2s) using animal models and human samples.

Research Highlights

1. July 2017, study entitled “Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease” was published in the Journal of Allergy and Clinical Immunology.  This article was highlighted in the journal’s Editor’s Choice feature.
2. August 2017, study entitled “Leukotriene C4 potentiates IL-33-induced group 2 innate lymphoid cell activation and lung inflammation” was published in the Journal of Immunology.
3. July 2013, study entitled “Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production” was published in the Journal of Allergy and Clinical Immunology.
4. May 2011, study entitled “The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling” was published in Nature Medicine.